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Abstract
Background: The myasthenia gravis is twice as common in women as in men and frequently
affects young women in the second and third decades of life, overlapping with the childbearing
years. Generally, during pregnancy in one third of patients the disease exacerbates, whereas in two
thirds it remains clinically unchanged. Complete remission can occur in some patients.
Methods: To describe the clinical course, delivery and neonatal outcome of 18 pregnant women
with the diagnosis of myasthenia gravis. Retrospective chart review of pregnant patients with
myasthenia gravis, followed at the National Institute of Perinatology in Mexico City over an 8-year
period. Data was abstracted from the medical records on the clinical course during pregnancy,
delivery and neonatal outcome.
Results: From January 1, 1996 to December 31, 2003 18 patients with myasthenia gravis were
identified and included in the study. The mean ± SD maternal age was 27.4 ± 4.0 years. During
pregnancy 2 women (11%) had an improvement in the clinical symptoms of myasthenia gravis, 7
women (39%) had clinical worsening of the condition of 9 other patients (50%) remained clinically
unchanged. Nine patients delivered vaginally, 8 delivered by cesarean section and 1 pregnancy
ended in fetal loss. Seventeen infants were born at mean ± SD gestational age of 37.5 ± 3.0 weeks
and a mean birth weight of 2710 ± 73 g. Only one infant presented with transient neonatal
myasthenia gravis. No congenital anomalies were identified in any of the newborns.
Conclusions:  The clinical course of myasthenia gravis during pregnancy is variable, with a
significant proportion of patients experiencing worsening of the clinical symptoms. However,
neonatal transient myasthenia was uncommon in our patient population.
Background
Myasthenia gravis (MG) is an acquired, neuromuscular,
autoimmune disease that presents clinically with weak-
ness and fatigue of the skeletal muscles. The disorder is
characterized by a decrease of the number of acetylcholine
receptors in the neuromuscular plates, due to an
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autoimmune process mediated by antibodies directed
against the alpha-subunit of the nicotine receptor of the
acetylcholine [1]. The disease is twice as common in
women as in men and frequently affects young women in
the second and third decades of life, overlapping with the
childbearing years [2,3]. Generally, during pregnancy in
one third of patients the disease exacerbates, whereas in
two thirds it remains clinically unchanged [4-8]. Of the
women who experience worsening, it usually occurs dur-
ing the first trimester. Signs and symptoms of MG in preg-
nant women tend to improve during the second and third
trimesters coinciding with the physiological immunosup-
pression which normally takes place in that period. Com-
plete remission can occur in some patients [4-8].
Papazian [9] reported a 21% incidence of transient neona-
tal myasthenia gravis (TNMG) on infants born to mothers
with MG. In this report 67% of infants developed TNMG
within the first few hours after birth and within the first 24
hours of life in 78% of neonates [9]. Onset of TNMG
beyond 3 days after birth has not been reported. Two clin-
ical forms of TNMG have been described: typical (71%)
and atypical (29%). Clinical features of the atypical form
include the presence of arthrogriposis multiplex congen-
ita (AMC) in the fetus or newborn [10]. The severity of
AMC in the infant is variable and does not co-relate with
neither the severity of maternal MG during pregnancy, or
if it is the first or subsequent pregnancies [10].
In anti acetylcholine-receptor (anti-AchR) antibody-asso-
ciated AMC, fetal or neonatal death is common. The pos-
sible mechanisms could be crossing of maternal
antibodies through the placenta with consequent block-
age of the function of the fetal isoform of the AchR leading
to fetal paralysis causing AMC. In the typical form of
TNMG the usual clinical findings include poor sucking
and generalized hypotonia [11].
Other reported clinical manifestations are week cry (60%
to 70%), facial diplegia or paresis (37 to 60%), swallow-
ing and sucking difficulties (50 to 71%), and mild respi-
ratory distress [9-11]. Ptosis (15%) and ophthalmoparesis
(8%) are less common. Respiratory distress requiring
assisted mechanical ventilation can occur in severe cases
(29%) [9,10,12]. Response to an oral or parenteral anti-
cholinesterase agent is usually very good. Complete recov-
ery is expected in less than 2 months in 90% of patients
and by 4 months of age in the remaining 10% [9,10,12].
It is not clear why only some babies develop TNMG, but
the ability of the mother's serum antibodies to bind to the
fetal isoform of the AchR in newborn may be a contribut-
ing factor [12].
The purpose of our present study was to report on the clin-
ical course, delivery and neonatal outcome of pregnant
women with the diagnosis of myasthenia gravis, followed
in our perinatal center.
Methods
Patient population
From January 1,1996 to December 31, 2003, 18 pregnant
women with MG were treated during pregnancy and
delivered at the National Institute of Perinatology, a terti-
ary referral center in Mexico City, Mexico. The clinical
course of the disease during pregnancy, labor and post-
partum period was reviewed, as well as the neonatal
period in the 17 infants born to MG mothers. All clinical
data was ascertained after reviewing and collecting data
from the patient's medical records. The diagnosis of
myasthenia gravis was made on clinical grounds and con-
firmed by positive edrophonium chloride and electromy-
ography tests [13,14]. Transient neonatal myasthenia
gravis was diagnosed on the bases of clinical signs of gen-
eralized hypotonia, sucking disturbances, weak cry and
respiratory difficulties.
Criteria for defining clinical improvement or deterioration
After reviewing the medical records of patients the follow-
ing criteria was used to define clinical change of MG dur-
ing pregnancy: a) the first was the type and dosage of
medications that the patient received before, during and
after pregnancy. Data was collected on the type and doses
of medications administered to the patient during the 3
periods, b) the second parameter was the stage of the dis-
ease according the Osserman's classification before, dur-
ing and after pregnancy.
The criteria for improvement, unchanged or worsening of
MG during pregnancy were the following: 1) Remission:
those patients that presented a total disappearance of the
symptoms (Osserman's stage 0) and who did not require
any specific medication, 2) Improvement: patients who
had clinical improvement of the symptoms and decrease
of the dosage of the medications that they received before
pregnancy by 30% or more, 3) No change: patients with
no clinical change in their symptoms (According to Osser-
man's classification) and same doses of medications com-
pared with before pregnancy. 4) Deterioration: patients
who had a deterioration of the disease (worsening of the
Osserman's stage) and an increase in the dosages of med-
ications compared with before the pregnancy, or the need
for immunosuppressant drugs such as azathioprine and/
or prednisone.
The Osserman's classification used in this study was the
one used by the Myasthenia Gravis Foundation of Amer-
ica: grade I: any ocular muscle weakness; grade II: mild
weakness affecting other than ocular muscles; III: moder-
ate weakness affecting other than ocular muscles; IV
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grade V: Defined by tracheal intubation, with or without
mechanical ventilation, except when employed in routine
postoperative management [15].
Patient follow-up
In the first two trimesters all patients were seen in the
clinic once a month, every 15 days between 32 and 36
weeks, and weekly after 36 weeks of gestation. During
every visit the dosage of the medications, and the Osser-
man's stage were reviewed. All patients were seen by a
team of obstetricians and clinical neurologists.
Statistical analysis
Descriptive statistics was used to compute the results.
Results
During the study period 18 pregnant women with MG
were seen at the hospital and had the medical records
available for review. The mean ± SD maternal age was
27.4 ± 4.0 years. Before pregnancy 3 patients (17%) were
in remission (Osserman's stage 0) and 15 patients (83%)
were classified as Osserman's stage II. All the patients were
clinically stable before pregnancy. Of the 15 patients with
in stage II, 13 (86%) used pyridostigmine, one used pyri-
dostigmine plus steroids (7%), and one used pyridostig-
mine, azathioprine and steroids. Thymectomy was
performed in 17 patients (94%) before the pregnancy.
The mean length of time from the start of symptoms to
thymectomy was 24.0 months (range: 1–168 months).
Other clinical conditions were also diagnosed in 5
patients (28%) before pregnancy: 3 (17%) had impaired
glucose tolerance and 2 autoimmune thyroiditis (11%).
Serum antibodies against the human acetylcholine recep-
tor assayed by standard RIA were positive in 14 patients
(77%). The patients became pregnant at a mean of 2 years
post-thymectomy. In our center we prefer to do the
thymectomy first and then when the patient is stable we
recommend the pregnancy. This is not a generalized pro-
tocol in many centers but the majority of our patients
were in good conditions before the pregnancy.
During pregnancy 9 patients (50%) did not change the
clinical status compared with before pregnancy, 2 (11%)
had improvement and 7 (39%) had worsening of the MG.
Of the seven patients who deteriorated, one did so in the
first trimester and six in the second trimester. Only one
patient experienced a myasthenic crisis during pregnancy.
During pregnancy 11 patients (61%) received pyridostig-
mine, one patient (6%) received pyridostigmine plus ster-
oids and another (6%) received pyridostigmine, steroids,
and azathioprine. The pregnancy in two patients (11%)
was complicated by eclampsy; one woman was diagnosed
with chorioamnionitis and another with thrombocytope-
nia. Pregnancy duration was 37.5 ± 3.0 weeks (range 29–
41 weeks). The clinical characteristics of patients is shown
in Table 1.
Table 2 shows the delivery mode and neonatal outcome
of our patients. Eight patients were delivered by caesarian
section. The other ten were delivered by vaginal delivery
(one forceps assisted), one of these products was a
stillbirth.
Seventeen infants were born at mean ± SD gestational age
of 37.5 ± 3.0 weeks and a mean birth weight of 2710 ± 73
g. Only one infant presented with transient neonatal
myasthenia gravis. This baby presented with sucking diffi-
culties, which resolved spontaneously by day 7 and did
not require any specific treatment. The patient with
myasthenic crisis delivered by spontaneous vaginal deliv-
ery at 37 weeks. The weight of the newborn was 2800 g
without complications. No congenital anomalies were
identified in any of the newborns.
Table 1: Patient characteristics
Variable Mean ± SD, median (range), # of patients (%)
Maternal variables
Maternal Age (years) 27.4 ± 4.04
Length of time from diagnosis to thymectomy (months) 24 (1–168)
Period of time from thymectomy to pregnancy (months) 24 (6–36)
Duration of pregnancy (weeks) 37.5 ± 3.0 (29 to 41)
Previous thymectomy (%) 17 (94%)
Clinical course of disease during pregnancy
No change 9 (50%)
Improvement 2 (11%)
Deterioration 7 (39%)BMC Musculoskeletal Disorders 2004, 5:42 http://www.biomedcentral.com/1471-2474/5/42
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Discussion
Myasthenia gravis is not rare among women of reproduc-
tive age, the reported incidence ranges from 1:10,000 to
1:50,000 [3]. Literature describing the clinical course of
pregnant myasthenic women mostly consists of single
case reports and case series [6-8]. Generally it has been
assumed that pregnancy is associated with physiological
immunosuppression. There is evidence, as yet unex-
plained, that polymorphonuclear leukocyte chemotaxis
and adherence functions are depressed beginning in the
second trimester and continuing during the rest of the
pregnancy. It is possible that these depressed leukocyte
functions of pregnant women account in part for the
improvement observed in some autoimmune diseases. It
may also explain the increased susceptibility to certain
infections [17]. On the other hand it is well known that
some diseases could exacerbate during the pregnancy.
This has been reported for example in patients with sys-
temic lupus erythematosus and myasthenia gravis
[16,17]. The clinical course of myasthenia gravis in preg-
nancy is considered to be unpredictable. It has been
reported that: a) approximately one third of patients
remain the same, one third improve, and the remaining
one third worsens, b) the course in one pregnancy does
not predict the course in subsequent pregnancies, c) exac-
erbations occur equally in all three trimesters and 4) ther-
apeutic termination does not demonstrate a consistent
benefit in cases of first trimester exacerbation [4,6-9,18].
Schlezinger [4] described the course of MG during preg-
nancy in 22 myasthenic women with a total of 33 preg-
nancies. He showed that in one third of the pregnant
woman an exacerbation occurred, whereas two thirds
showed no change or a remission occurred. In his series
the exacerbation usually occurred during the first trimes-
ter, with minor clinical changes during the second and
third trimesters [4]. Djelmis et al [8] reviewed their expe-
rience with 69 pregnancies among 65 women with MG
managed over a 28 year-period. 24.6% of patients showed
an improvement during the pregnancy, 44.9% did not
change and 30.4% suffered exacerbations. In Djelmis et al
[8] report the deterioration was observed in the last 4
weeks of pregnancy and in the puerperium. In another
study Mitchell et al [6] reported the clinical course of 11
cases of pregnant myasthenia gravis patients. 27.2 % had
improvement and 72.7% deteriorated during pregnancy.
The deterioration was observed in the third trimester in all
patients. One of their patients suffered respiratory failure.
They concluded that there were no predictive factors to
identify the mother at risk of exacerbation during preg-
nancy and the risk of neonatal myasthenia gravis. Batochi
et al [7] evaluated the course of 47 women who became
pregnant after the onset of MG. During pregnancy 42%
had no change, 39% improved and 19% got worse. In the
experience of Batochi et al [7] the clinical worsening was
more frequent in the second trimester and two patients
developed respiratory failure. He concluded that the
course of the myasthenia gravis during gestation is highly
variable and unpredictable and can change in subsequent
pregnancies. Recently Picone at al [18] in a series of 12
patients showed worsening in 42% of patients during
pregnancy.
Our study showed a frequency of worsening of 33%,
being an intermediate frequency compared with the
reported frequencies of 15 to 55%. The majority of our
patients showed that the worsening occurred in the sec-
ond trimester as in the Batochi et al [7] series. In the series
of Osserman [4] and Djlemis et al [8] the worsening was
observed in the third trimester. It is clear from these
reports that the clinical course of the disease during preg-
nancy is highly variable, and difficult to predict. In our
study 8 patients had a cesarean section for delivery (47%)
and 9 (53%) delivered vaginally (one by forceps extrac-
tion). In one patient the pregnancy ended in a stillbirth.
Djelmis et al [8] reported vaginal deliver in 82%, Batochi
et al [7] in 70%, Mitchel et al [6] in 90% and Picone at al
[18] in 58%. Our study showed a rate of cesarean section
of 47%, similar to the rate of 42% reported by Picone et al
[18]. In a recent study Hoff et al [19] reported the results
of a retrospective cohort in Norway. The study population
consisted of 127 births to mothers with MG compared
Table 2: Delivery and neonatal outcome
Variable Mean ± SD, # of patients (%)
Type of delivery (n = 18)
Vaginal (without Forceps)* 9 (50%)
Vaginal (Forceps) 1 (6%)
Caesarian 8 (44%)
Neonatal outcome (n = 17)
Birth weight (g) 2710 ± 73
Neonatal transient myasthenia gravis 1 (6%)
*One vaginal delivery was a stillbirth.BMC Musculoskeletal Disorders 2004, 5:42 http://www.biomedcentral.com/1471-2474/5/42
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with a reference group of 1.9 million births to mothers
without MG. They showed that women with MG had a
higher rate of complications at delivery, and in particular
the risk of preterm rupture of amniotic membranes was
three times higher in the MG group compared with the
reference group. The rate of interventions during birth was
raised and cesarean sections doubled. They concluded
that MG is associated with an increased risk of complica-
tions during delivery, leading to a higher need for surgical
interventions.
Regarding the newborns, our study showed that their
weight is lower compared with other studies [6,7]. This
may be explained by racial differences between our popu-
lation and the population reported by others. The inci-
dence of TNMG has been reported between 9 and 30%
[6,7] Typical clinical findings in the typical form of TNMG
are poor sucking and generalized hypotonia. Other mani-
festations are swallowing and sucking difficulties and
mild respiratory distress. Response to oral or parenteral
anticholinesterase agents is usually very good. Complete
recovery is expected in less than 2 months in 90% of
patients and in the remaining 10% by 4 months [9,10],
[12,13]. Only 5% of our patients presented with TNMG,
which is less than the rate reported by others. The reason
for this lower rate is unexplained but it could be due to
genetic variation as suggested by others [9].
In conclusion the present literature in pregnant patients
with myasthenia gravis is somewhat limited. It consists
mostly of case reports and case series. Our study adds to
the body of literature showing that about third of our
patients deteriorated during pregnancy, which was
observed in the second trimester. Our cesarean section
rate was high and the rate of TNMG was relatively low.
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